| Year ended December 31, | ||||||||||||||||||||||||
| 2012 | 2011 | |||||||||||||||||||||||
| As reported | Adjustments | As restated | As reported | Adjustments | As restated | |||||||||||||||||||
| Operating expenses | ||||||||||||||||||||||||
| R Research and development | $ | 49,219 | $ | - | $ | 49,219 | $ | 85,281 | $ | - | $ | 85,281 | ||||||||||||
| General and administrative | 6,715 | - | 6,715 | 7,857 | - | 7,857 | ||||||||||||||||||
| Total operating expense | 55,934 | - | 55,934 | 93,138 | - | 93,138 | ||||||||||||||||||
| Loss from operations | (55,934 | ) | - | (55,934 | ) | (93,138 | ) | - | (93,138 | ) | ||||||||||||||
| Other income (expense): | ||||||||||||||||||||||||
| In Other income (expense) | (111 | ) | - | (111) | 606 | - | 606 | |||||||||||||||||
| Interest expense | (3,354 | ) | - | (3,354 | ) | (2,803 | ) | - | (2,803 | ) | ||||||||||||||
| Mark-to-market adjustment of warrants liability | - | 14,070 | 14,070 | - | (3,738 | ) | (3,738 | ) | ||||||||||||||||
| Beneficial conversion features | - | - | - | - | - | - | ||||||||||||||||||
| Total other income (expense) | (3,465 | ) | 14,070 | 10,605 | (2,197 | ) | - | (5,935 | ) | |||||||||||||||
| Net loss | $ | (59,399 | ) | $ | 14,070 | $ | (45,329 | ) | $ | (95,335 | ) | $ | (3,738 | ) | $ | (99,073 | ) | |||||||
| N Net loss per share - basic and diluted | $ | (8.22 | ) | $ | 1.95 | $ | (6.27 | ) | $ | (20.38 | ) | $ | (0.80 | ) | $ | (21.18 | ) | |||||||
| Weighted average shares used in net income (loss) per share - basic and diluted | 7,225,406 | - | 7,225,406 | 4,677,210 | - | 4,677,210 | ||||||||||||||||||